Oncology Biosimilars Market: By Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others) By Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, and Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Oncology Biosimilars Market size was valued at USD 3.5 billion in 2022 and is poised to grow at a significant CAGR of 29.0% from 2023-2029. According to the World Health Organization (WHO), cancer is one of the second most important causes of death worldwide. According to WHO figures, 9.6 million people died from cancer in 2018. These figures emphasize the importance of reducing cancer-related fatalities. The growth of the oncology biosimilars market has been fueled by an increase in cancer cases such as lung cancer and breast cancer, a vulnerable aging population, and increasing research and development activities by multiple pharmaceutical companies. The Biosimilars are biological medications demonstrated to be highly similar to the original drug in terms of potency, safety, and purity. Oncology biosimilars are used to treat a variety of cancers and symptoms as therapeutic, diagnostic, or preventive agents. The oncology biosimilars are the first choice for many cancer patients, resulting in a faster growth rate. Pharmaceutical companies are capitalizing on the expanding biosimilar market's growth potential by investing in their research and development (R&D) operations to support the development and production of new biosimilars. For example, Coherus and Junshi Biosciences announced a partnership in February 2021 in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus intends to use cash from its commercial biosimilar company to develop a top immuno-oncology franchise. In addition, Biocon, India's largest biotechnology business, invested in Pfizer Healthcare's assets to establish an R&D facility to accelerate biosimilar development. Moreover, FDA has approved Oncology biosimilars in large numbers, a trend that is expected to continue in the future years. The FDA approved two significant biosimilars: filgrastim-sndz (Zarxio) and bevacizumab-awwb (Mvasi). The impact of the increasing approval rate on market maturity will be intriguing to watch. Approaching patent expirations of branded biologics and increased research and development (R&D) activity by biosimilar manufacturers are some of the critical growth-inducing factors for the market.

Oncology Biosimilars Market Key Developments:
  • In December 2020, Amgen received United States Food and Drug Administration (USFDA) approval for RIABNI (rituximab-arrx). RIABNI (rituximab-arrx) is a biosimilar to rituximab used to treat adult patients suffering from non-Hodgkin lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, and microscopic polyangiitis (MPA).

Oncology Biosimilars Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

29%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Oncology Biosimilars Market Dynamics

According to the American Journal of Managed Care, biosimilars are cheaper than their parent/branded counterparts, and this saves money while giving patients access to highly effective medicines. Biosimilars have more affordable R&D expenses than originator biologics, and Biosimilars are less expensive since R&D expenses are reduced. Biosimilars with lower prices tend to drive down the costs of reference biologics due to price rivalry among manufacturers. Biosimilar medications' considerable cost-to-benefit ratio is predicted to increase their demand in the coming years. However, biosimilar development is a time-consuming and expensive procedure requiring significant financial inputs, technical capabilities, clinical trial knowledge, scientific standards, and quality control systems. The oncology biosimilars market is limited by a lack of understanding among primary care physicians (PCPs) and specialists about biosimilars.

Oncology Biosimilars Market Segmentation

By Drug Type
  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others
By Cancer Type
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The Oncology Biosimilars Market is projected to expand at a CAGR of 29.0% during the forecast period  

Bitcoin, Celltrion inc, Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, STADA Arzneimittel AG

North America is the fastest-growing region for Oncology Biosimilars Market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Oncology Biosimilars Market Introduction 
2.1.Global Oncology Biosimilars Market  - Taxonomy
2.2.Global Oncology Biosimilars Market  - Definitions
2.2.1.Drug Type
2.2.2.Cancer Type
2.2.3.Region
3.Global Oncology Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Oncology Biosimilars Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Oncology Biosimilars Market  By Drug Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Monoclonal Antibody
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Immunomodulators
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. G-CSF
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Hematopoietic Agents
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Oncology Biosimilars Market  By Cancer Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Lung Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Colorectal Cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Cervical Cancer
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Breast Cancer
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Oncology Biosimilars Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America Oncology Biosimilars Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Monoclonal Antibody
8.1.2.Immunomodulators
8.1.3.G-CSF
8.1.4.Hematopoietic Agents
8.1.5.Others
8.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Lung Cancer
8.2.2.Colorectal Cancer
8.2.3.Cervical Cancer
8.2.4.Breast Cancer
8.2.5.Others
8.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Oncology Biosimilars Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Monoclonal Antibody
9.1.2.Immunomodulators
9.1.3.G-CSF
9.1.4.Hematopoietic Agents
9.1.5.Others
9.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Lung Cancer
9.2.2.Colorectal Cancer
9.2.3.Cervical Cancer
9.2.4.Breast Cancer
9.2.5.Others
9.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Oncology Biosimilars Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Monoclonal Antibody
10.1.2.Immunomodulators
10.1.3.G-CSF
10.1.4.Hematopoietic Agents
10.1.5.Others
10.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Lung Cancer
10.2.2.Colorectal Cancer
10.2.3.Cervical Cancer
10.2.4.Breast Cancer
10.2.5.Others
10.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) Oncology Biosimilars Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Monoclonal Antibody
11.1.2.Immunomodulators
11.1.3.G-CSF
11.1.4.Hematopoietic Agents
11.1.5.Others
11.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Lung Cancer
11.2.2.Colorectal Cancer
11.2.3.Cervical Cancer
11.2.4.Breast Cancer
11.2.5.Others
11.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America Oncology Biosimilars Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Monoclonal Antibody
12.1.2.Immunomodulators
12.1.3.G-CSF
12.1.4.Hematopoietic Agents
12.1.5.Others
12.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Lung Cancer
12.2.2.Colorectal Cancer
12.2.3.Cervical Cancer
12.2.4.Breast Cancer
12.2.5.Others
12.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Biocoin
13.2.2.Celltrion inc.
13.2.3.Reddy's Laboratories Ltd.
13.2.4.Intas Pharmaceuticals Ltd.
13.2.5.STADA Arzneimittel AG
13.2.6.Pfizer inc.
13.2.7.Apotex inc.
13.2.8.Teva Pharmaceutical Industries Ltd.
13.2.9.Sandoz International GmbH
13.2.10.BIOCAD
13.2.11.Amgen
13.2.12.Hospira
14. Research Methodology 
15. Appendix and Abbreviations 
  • Biocoin
  • Celltrion inc.
  • Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • STADA Arzneimittel AG
  • Pfizer inc.
  • Apotex inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • BIOCAD
  • Amgen
  • Hospira

Adjacent Markets